About Unicycive Therapeutics
Unicycive Therapeutics (NASDAQ:UNCY) is a biotechnology firm that focuses on developing and commercializing innovative treatments for patients with kidney disease and renal conditions. Their portfolio includes Renazorb, a phosphate binder for managing hyperphosphatemia in patients with chronic kidney disease, and UNI-494, an investigational drug for the treatment of acute kidney injury, underscoring their commitment to addressing unmet medical needs in renal care. The company's objective is to improve patient outcomes and quality of life through the discovery, development, and commercialization of these novel therapeutic candidates. With a patient-centered approach, Unicycive Therapeutics strives to advance renal care and meet the complex challenges faced by individuals with kidney diseases.
Snapshot
Operations
Products and/or services of Unicycive Therapeutics
- Renazorb, a lanthanum-based phosphate binder for the management of hyperphosphatemia in patients with chronic kidney disease.
- UNI-494, an investigational new drug aimed at treating acute kidney injury by preventing cell death and inflammation.
- Kidney transplantation services, focusing on improving outcomes through novel therapeutic approaches.
- Research in kidney disease biomarkers, aiming to enhance diagnostic methods and therapeutic monitoring.
- Consulting and partnership services for the development and commercialization of kidney disease treatments and diagnostics.
Unicycive Therapeutics executive team
- Dr. Shalabh K. Gupta M.D., MPAFounder, Chairman, CEO & President
- Dr. Pramod Gupta Ph.D.Executive Vice President of Operations
- Mr. Douglas Jermasek M.B.A.Executive Vice President of Corporate Strategy
- Mr. John W. Townsend CPAChief Financial Officer